Improvement of the verification of liver fibrosis using new minimally invasive markers in patients with metabolic-associated steatotic liver disease

Authors

  • Yu. M. Stepanov SI «Institute Gastroenterology of the National Academy of Medical Sciences of Ukraine» 96, Slobozhanskyi Ave., Dnipro, Ukraine, 49074 Author
  • V. I. Didenko SI «Institute Gastroenterology of the National Academy of Medical Sciences of Ukraine» 96, Slobozhanskyi Ave., Dnipro, Ukraine, 49074 Author
  • I. A. Klenina SI «Institute Gastroenterology of the National Academy of Medical Sciences of Ukraine» 96, Slobozhanskyi Ave., Dnipro, Ukraine, 49074 Author
  • O. M. Tatarchuk SI «Institute Gastroenterology of the National Academy of Medical Sciences of Ukraine» 96, Slobozhanskyi Ave., Dnipro, Ukraine, 49074 Author
  • O. P. Petishko SI «Institute Gastroenterology of the National Academy of Medical Sciences of Ukraine» 96, Slobozhanskyi Ave., Dnipro, Ukraine, 49074 Author

DOI:

https://doi.org/10.7124/bc.000AC2

Keywords:

metabolically associated fatty liver disease, fibrosis of liver, cytokines, biochemical markers

Abstract

Aim. To identify new minimally invasive serum markers of fibrotic liver changes in patients with MASLD and compare them with well-known fibrosis diagnostic indices. Conclusions. Comparison of the diagnostic value of biological markers obtained in our study with well-known fibrosis scores showed that TNFα/IL-10, NOMA-IR, and α1-acid glycopeptide content are more sensitive and specific. New possible biomarkers for predicting the development of liver fibrosis in patients with MASLD were obtained. A largest cogort and additional studies are needed to validate the proposed biomarkers panel.
biopolym.cell-2024-40-3-cover.png

Downloads

Published

2024-09-10

Issue

Vol. 40 No. 3 (2024)

Section

Chronicle and Information